Access cutting-edge sickle cell disease treatment through this clinical trial at a research site in Phoenix. Study-provided care at no cost to qualified participants.
Access sickle cell disease specialists in Phoenix at no cost
This study follows strict safety protocols and ethical guidelines
All study-related sickle cell disease treatment provided free
Etavopivat is a new medicine under development for treating blood disorders like sickle cell disease and thalassaemia. Sickle cell disease and thalassaemia are inherited blood disorders that affect haemoglobin. Haemoglobin is the protein that carries oxygen through the body. This study is looking into how safe treatment with etavopivat is and how well it works over a long period of time. The study will last for up to 264 weeks, but it will end earlier if etavopivat is approved in the participant
Sponsor: Novo Nordisk A/S
Check if you qualify for this sickle cell disease clinical trial in Phoenix, AZ
If you're searching for sickle cell disease treatment options in Phoenix, AZ, this clinical trial may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.
Our Phoenix research site is actively enrolling participants for this clinical trial. You'll receive care from experienced sickle cell disease specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.